Intra-cellular therapies announces closing of $460 million public offering including full exercise of underwriters' option to purchase additional shares

New york, jan. 07, 2022 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. in addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares.
ITCI Ratings Summary
ITCI Quant Ranking